Wyeth becomes the first foreign company that sell HMO infant formula added with two HMOs in China
Wyeth Nutrition announced that its first illuma HMO growing-up infant formula added with two human milk oligosaccharides (HMOs) is now available throughout China, which makes Wyeth Nutrition the first multinational company that sells the HMO infant formula in the market just two months after two HMOs were newly authorized as food additives by China’s National Health Commission (NHC). Before that, the company was also the first foreign company that manufacture HMO infant formula in China, just one month after NHC’s approval, at the company’s GMP-level factory in Suzhou. Now, Chinese consumers can order the first HMO infant formula added with two HMOs in China via various channels, including the illuma flagship store on Tmall, the Wyeth flagship store on JD.COM, and numerous offline stores across the country.
The NHC announced the approval of two HMOs, 2′-fucosyllactose (2′-FL) and lacto-N-neotetraose (LNnT), as new food additives in formula products, and HMOs quickly became the focus of China’s infant formula industry. Many brands were competing to launch HMO-containing formulas. Wyeth Nutrition was the first foreign company in China’s infant formula industry to respond to that announcement. It took the lead to launch the first illuma HMO growing-up infant formula in November. This expanded the brand’s portfolio of premium growing-up infant formulas and provided a new option containing ingredients that can modulate immune responses for Chinese babies. The product is now available across channels in China. People can order it from the official flagship store of illuma on Tmall and JD.COM, as well as various physical stores. This new product is designed to provide multiple nutrients for babies above 3 years old.
